Article Text

AB0702 Improvement of fatigue in patients with spondyloarthritis treated with anti-tnf therapy: a prospective study in a real-life setting
  1. S Desouches,
  2. E Gaigneux,
  3. K Louati,
  4. L Lemeunier,
  5. C Beauvais,
  6. J Sellam,
  7. F Berenbaum
  1. Rheumatology, APHP Saint-Antoine, paris, France


Background Besides randomized controlled trials evaluating biologic agents on fatigue, the impact of anti-TNF therapy on this crucial symptom has been poorly assessed in a real-life setting (1).

Objectives To assess the early effect of etanercept (ETN) on fatigue-related outcomes in spondyloarthritis (SpA) patients in a real-life setting.

Methods This prospective study included patients with active SpA fulfilling ASAS 2009 axial or peripheral criteria requiring an anti-TNF. All patients were treated with ETN 50mg weekly. BASDAI, BASFI, functional assessment of chronic illness therapy-fatigue (FACIT-F) (0 maximum and 52 the minimum of fatigue) and visual analogic scale of fatigue (VAS-F) (0 the minimum -100 maximum of fatigue) were assessed at inclusion at the time of ETN beginning (M0) and 4±1 months later (M4).

The primary outcome was the M0-M4 change of VAS-F. The secondary outcomes were i) the M0-M4 change of FACIT-F ii) the frequency of patients who met improvement according to FACIT-F (defined as the minimal clinically important difference of FACIT-F corresponding to a 4-points decrease (FACIT-F responders). To determine whether fatigue change was related to disease activity improvement, a correlation between M0-M4 changes of BASDAI and VAS-F or FACIT-F was determined.

Results 30 SpA patients were enrolled (60% women, mean age ± standard deviation 39±8 years-old, axial SpA 83%, mean BMI 26±4, 80% ETN as a 1st line). Mean BASDAI improved at M4 (M0 48±20 versus M4 36.5±22; p=0.04) as well as VAS-F (M0 69±18 vs M4 52±24; p=0.01). The frequency of patients having VAS-F>50/100 was 86% at M0 and decreased at 36% at M4. Conversely, no significant change was observed concerning FACIT-F (M0 24.5±24 versus M4 28.8±11: p=0.36). At M4, 64% patients were FACIT-F responders. FACIT-F and VAS-F M0-M4 changes were highly correlated (r=0.78, p<0.0001).

Despite no correlation between BASDAI and FACIT-F M0-M4 changes (r=0.36, p=0.1), a trend was observed for BASDAI and VAS-F M0-M4 changes in the same fashion (r=0.36, p=0.07). Interestingly, there was no baseline clinical characteristic associated with subsequent better fatigue improvement.

Conclusions This real-life study investigating the early effect of etanercept therapy on fatigue in SpA patients showed that fatigue (according to VAS-F) significantly improved while effect on FACIT-F was less pronounced. This improvement was explained, only in part, by disease activity improvement.


  1. Chauffier K, et al Clin Exp Rheumatol. 2013;31:864–70.


Acknowledgements Grant from Pfizer.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.